

SPECIAL FEATURES

Highlights of This Issue 1125

CCR Translations

1127 For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity

Ivan Marquez-Rodas, María Angela Aznar, Antonio Calles, and Ignacio Melero

*See related article, p. 1185***1130** Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4

Sergio A. Quezada and Karl S. Peggs

*See related article, p. 1233***1133** First CAR to Pass the Road Test: Tisagenlecleucel's Drive to FDA Approval

Mark B. Geyer

*See related article, p. 1142***1136** The Molecular Profiling Lottery: More Accuracy, Less Precision, and No Cost

Mark J. Ratain

*See related article, p. 1239***1139** Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer

Elahe A. Mostaghel

See related article, p. 1291

CCR Drug Updates

1142 FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Maura C. O'Leary, Xiaobin Lu, Ying Huang, Xue Lin, Iftekhar Mahmood, Donna Przepiorka, Denise Gavin, Shiwon Lee, Ke Liu, Bindu George, Wilson Bryan, Marc R. Theoret, and Richard Pazdur

See related commentary, p. 1133

Review

1147 Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities

Matthew R. Trendowski, Omar El Charif, Paul C. Dinh Jr, Lois B. Travis, and M. Eileen Dolan

CLINICAL TRIALS: TARGETED THERAPY

1156 Inhibition of mTOR Signaling and Clinical Activity of Rapamycin in Head and Neck Cancer in a Window of Opportunity Trial

Terry A. Day, Keisuke Shirai, Paul E. O'Brien, Maria Gisele Matheus, Kristina Godwin, Amit J. Sood, Anvesh Kompelli, Julie A. Vick, Daniel Martin, Lynn Vitale-Cross, Juan Luis Callejas-Varela, Zhiyong Wang, Xingyu Wu, Olivier Harismendy, Alfredo A. Molinolo, Scott M. Lippman, Carter Van Waes, Eva Szabo, and J. Silvio Gutkind

1165 Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

Daniel J. George, Jean-Francois Martini, Michael Staehler, Robert J. Motzer, Ahmed Magheli, Frede Donskov, Bernard Escudier, Sherry Li, Michelle Casey, Olga Valota, Brigitte Laguerre, Allan J. Pantuck, Hardev S. Pandha, Anup Patel, Maria Lechuga, and Alain Ravaud

1174 Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies

Greg P. Coffey, Jiajia Feng, Andreas Betz, Anjali Pandey, Matt Birrell, Janet M. Leeds, Kenneth Der, Sabah Kadri, Pin Lu, Jeremy Segal, Y. Lynn Wang, Glenn Michelson, John T. Curnutte, and Pamela B. Conley

CLINICAL TRIALS: IMMUNOTHERAPY

1185 Intratumoral G100, a TLR4 Agonist, Induces Antitumor Immune Responses and Tumor Regression in Patients with Merkel Cell

Carcinoma

Shailender Bhatia, Natalie J. Miller, Hailing Lu, Natalie V. Longino, Dafina Ibrani, Michi M. Shinohara, David R. Byrd, Upendra Parvathaneni, Rima Kulikauskas, Jan ter Meulen, Frank J. Hsu, David M. Koelle, and Paul Nghiem




See related commentary, p. 1127

PRECISION MEDICINE AND IMAGING

1196 The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging

Benjamin M. Larimer, Emily Bloch, Sarah Nesti, Emily E. Austin, Eric Wehrenberg-Klee, Genevieve Boland, and Umar Mahmood

Table of Contents

- 1206** Preclinical Development and First-in-Human Imaging of the Integrin $\alpha_v\beta_6$ with [^{18}F] $\alpha_v\beta_6$ -Binding Peptide in Metastatic Carcinoma
Sven H. Hausner, Richard J. Bold, Lina Y. Cheuy, Helen K. Chew, Megan E. Daly, Ryan A. Davis, Cameron C. Foster, Edward J. Kim, and Julie L. Sutcliffe
- 1216** Evaluation of Emergent Mutations in Circulating Cell-Free DNA and Clinical Outcomes in Patients with Metastatic Colorectal Cancer Treated with Panitumumab in the ASPCCCT Study
Marc Peeters, Timothy Price, Michael Boedigheimer, Tae Won Kim, Paul Ruff, Peter Gibbs, Anne Thomas, Gaston Demonty, Kristina Hool, and Agnes Ang
- 1226** Residual Tumor Volume, Cell Volume Fraction, and Tumor Cell Kill During Fractionated Chemoradiation Therapy of Human Glioblastoma using Quantitative Sodium MR Imaging
Keith R. Thulborn, Aiming Lu, Ian C. Atkinson, Mohan Pauliah, Kathryn Beal, Timothy A. Chan, Antonio Omuro, Josh Yamada, and Michelle S. Bradbury
- 1233** Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3⁺ Regulatory T Cells (Tregs) in Human Cancers
 Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis Vence, Jennifer Wargo, James P. Allison, Antoni Ribas, and Padmanee Sharma
See related commentary, p. 1130
- 1239** Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials
 Ida Viller Tuxen, Kristoffer Staal Rohrberg, Olga Oestrup, Lise Barlebo Ahlborn, Ane Yde Schmidt, Iben Spanggaard, Jane P. Hasselby, Eric Santoni-Rugiu, Christina Westmose Yde, Morten Mau-Sørensen, Finn Cilius Nielsen, and Ulrik Lassen
See related commentary, p. 1136
- 1261** Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma
 Marissa Spino, Sylvia C. Kurz, Luis Chiriboga, Jonathan Serrano, Briana Zeck, Namita Sen, Seema Patel, Guomiao Shen, Varshini Vasudevaraja, Aristotelis Tsirigos, Carter M. Suryadevara, Joshua D. Frenster, Kensuke Tateishi, Hiroaki Wakimoto, Rajan Jain, Howard A. Riina, Theodore P. Nicolaides, Erik P. Sulman, Daniel P. Cahill, John G. Golfinos, Kumiko Isse, Laura R. Saunders, David Zagzag, Dimitris G. Placantonakis, Matija Snuderl, and Andrew S. Chi
- 1272** Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma
Inês Pires da Silva, Kevin Y.X. Wang, James S. Wilmott, Jeff Holst, Matteo S. Carlino, John J. Park, Camelia Quek, Matthew Wongchenko, Yibing Yan, Graham Mann, Douglas B. Johnson, Jennifer L. McQuade, Rajat Rai, Richard F. Kefford, Helen Rizos, Richard A. Scolyer, Jean Y.H. Yang, Georgina V. Long, and Alexander M. Menzies
- 1280** Distinct Biological Types of Ocular Adnexal Sebaceous Carcinoma: HPV-Driven and Virus-Negative Tumors Arise through Nonoverlapping Molecular-Genetic Alterations
Michael T. Tetzlaff, Jonathan L. Curry, Jing Ning, Oded Sagiv, Thomas L. Kandl, Bo Peng, Diana Bell, Mark Routbort, Courtney W. Hudgens, Doina Ivan, Tae-Boom Kim, Ken Chen, Agda Karina Eterovic, Kenna Shaw, Victor G. Prieto, Anna Yemelyanova, and Bitá Esmaeli
- 1291** Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression
Xiaomei Gao, Charles Dai, Shengsong Huang, Jingjie Tang, Guoyuan Chen, Jianneng Li, Ziqi Zhu, Xuyou Zhu, Shuirong Zhou, Yuanyuan Gao, Zemin Hou, Zijun Fang, Chengdang Xu, Jianyang Wang, Denglong Wu, Nima Sharifi, and Zhenfei Li
See related commentary, p. 1139
- 1302** FLI1 Exonic Circular RNAs as a Novel Oncogenic Driver to Promote Tumor Metastasis in Small Cell Lung Cancer
Lingyu Li, Wei Li, Naifei Chen, Haixin Zhao, Guang Xu, Yijing Zhao, Xin Pan, Xiaoying Zhang, Lei Zhou, Dehai Yu, Ailing Li, Ji-Fan Hu, and Jiuwei Cui
- 1318** Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis
Li-Peng Hu, Xiao-Xin Zhang, Shu-Heng Jiang, Ling-Ye Tao, Qing Li, Li-Li Zhu, Ming-Wei Yang, Yan-Miao Huo, Yong-Sheng Jiang, Guang-Ang Tian, Xiao-Yan Cao, Yan-Li Zhang, Qin Yang, Xiao-Mei Yang, Ya-Hui Wang, Jun Li, Gary Guishan Xiao, Yong-Wei Sun, and Zhi-Gang Zhang

TRANSLATIONAL CANCER MECHANISMS AND THERAPY

Table of Contents

1331 Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity

Steven E. Johnson, Andrey Ugolkov, Chad R. Haney, Gennadiy Bondarenko, Lin Li, Emily A. Waters, Raymond Bergan, Andy Tran, Thomas V. O'Halloran, Andrew Mazar, and Ming Zhao

1343 A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma

Lillian M. Guenther, Neekesh V. Dharia, Linda Ross, Amy Conway, Amanda L. Robichaud, Jerrel L. Catlett II, Caroline S. Wechsler, Elizabeth S. Frank, Amy Goodale, Alanna J. Church, Yuen-Yi Tseng, Rajarshi Guha, Crystal G. McKnight, Katherine A. Janeway, Jesse S. Boehm, Jaume Mora, Mindy I. Davis, Gabriela Alexe, Federica Piccioni, and Kimberly Stegmaier

1358 An Anti-CLL-1 Antibody-Drug Conjugate for the Treatment of Acute Myeloid Leukemia



Bing Zheng, Shang-Fan Yu, Geoffrey del Rosario, Steven R. Leong, Genee Y. Lee, Rajesh Vij, Cecilia Chiu, Wei-Ching Liang, Yan Wu, Cecile Chalouni, Jack Sadowsky, Vanessa Clark, Angela Hendricks, Kirsten Achilles Poon, Wayne Chu, Thomas Pillow, Melissa M. Schutten, John Flygare, and Andrew G. Polson

1369 Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer

Tilman D. Rachner, Sabine Kasimir-Bauer, Andy Göbel, Kati Erdmann, Oliver Hoffmann, Andrew Browne, Pauline Wimberger, Martina Rauner, Lorenz C. Hofbauer, Rainer Kimmig, and Ann-Kathrin Bittner

1379 A CK1 α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma

Jezabel Rodriguez-Blanco, Bin Li, Jun Long, Chen Shen, Fan Yang, Darren Orton, Sara Collins, Noriyuki Kasahara, Nagi G. Ayad, Heather J. McCrea, Martine F. Rousset, William A. Weiss, Anthony J. Capobianco, and David J. Robbins

1389 Long Noncoding RNA *LBCS* Inhibits Self-Renewal and Chemoresistance of Bladder Cancer Stem Cells through Epigenetic Silencing of *SOX2*

Xu Chen, Ruihui Xie, Peng Gu, Ming Huang, Jinli Han, Wen Dong, Weibin Xie, Bo Wang, Wang He, Guangzheng Zhong, Ziyue Chen, Jian Huang, and Tianxin Lin

1404 Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors *In Vitro* and *In Vivo*

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández-Montalván, Wilhelm Bone, Jens Schröder, Sabine Zitzmann-Kolbe, Hans Briem, Stefan Prechtel, Simon J. Holton, Ursula Mönning, Oliver von Ahsen, Sandra Johanssen, Arwed Cleve, Vera Pütter, Marion Hitchcock, Franz von Nussbaum, Michael Brands, Karl Ziegelbauer, and Dominik Mumberg

1415 Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness



So-Yeon Park, Ji-Young Kim, Jang-Hyun Choi, Jee-Heun Kim, Choong-Jae Lee, Pomila Singh, Shubhashish Sarkar, Jeong-Heum Baek, and Jeong-Seok Nam

CORRECTIONS

1430 Correction: Neratinib: Inching Up on the Cure Rate of HER2⁺ Breast Cancer?

Nisha Unni, Dhivya R. Sudhan, and Carlos L. Arteaga

1431 Correction: ER⁺ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

Angel L. Guerrero-Zotano, Thomas P. Stricker, Luigi Formisano, Katherine E. Hutchinson, Daniel G. Stover, Kyung-Min Lee, Luis J. Schwarz, Jennifer M. Giltane, Monica V. Estrada, Valerie M. Jansen, Alberto Servetto, Joaquín Gavilá, J. Alejandro Perez-Fidalgo, Ana Lluch, Antonio Llobart-Cussac, Mohamed Amine Bayar, Stefan Michiels, Fabrice André, Mónica Arnedos, Vicente Guillem, Amparo Ruiz-Simon, and Carlos L. Arteaga

1432 Correction: *PIK3CA* C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K α Inhibitors

Sarah Croessmann, Jonathan H. Sheehan, Kyung-min Lee, Gregory Sliwoski, Jie He, Rebecca Nagy, David Riddle, Ingrid A. Mayer, Justin M. Balko, Richard Lanman, Vincent A. Miller, Lewis C. Cantley, Jens Meiler, and Carlos L. Arteaga

1433 Correction: Association of FGFR1 with ER α Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER⁺ Breast Cancer

Luigi Formisano, Kimberly M. Stauffer, Christian D. Young, Neil E. Bhola, Angel L. Guerrero-Zotano, Valerie M. Jansen, Mónica M. Estrada, Katherine E. Hutchinson, Jennifer M. Giltane, Luis J. Schwarz, Yao Lu, Justin M. Balko, Olivier Deas, Stefano Cairo, Jean-Gabriel Judde, Ingrid A. Mayer, Melinda Sanders, Teresa C. Dugger, Roberto Bianco, Thomas Stricker, and Carlos L. Arteaga

Table of Contents


- 1434** Correction: HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2
Ariella B. Hanker, Joan T. Garrett, Mónica Valeria Estrada, Preston D. Moore, Paula González Ericsson, James P. Koch, Emma Langley, Sharat Singh, Phillip S. Kim, Garrett M. Frampton, Eric Sanford, Philip Owens, Jennifer Becker, M. Reid Groseclose, Stephen Castellino, Heikki Joensuu, Jens Huober, Jan C. Brase, Samira Majjaj, Sylvain Brohée, David Venet, David Brown, José Baselga, Martine Piccart, Christos Sotiriou, and Carlos L. Arteaga
- 1435** Correction: ^{18}F -Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials
Yingbing Wang, Karen L. Ayres, Debra A. Goldman, Maura N. Dickler, Aditya Bardia, Ingrid A. Mayer, Eric Winer, Jill Fredrickson, Carlos L. Arteaga, José Baselga, Henry C. Manning, Umar Mahmood, and Gary A. Ulaner
- 1436** Correction: Is There a Future for AKT Inhibitors in the Treatment of Cancer?
Valerie M. Jansen, Ingrid A. Mayer, and Carlos L. Arteaga
- 1437** Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltman, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, and Justin M. Balko

 AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows diffuse intratumoral immune cell infiltration into a Merkel cell carcinoma (MCC) metastasis after intratumoral injections of G100, a toll-like receptor 4 agonist. This local inflammation was associated with systemic benefit in this patient with stage IV MCC with a durable objective response ongoing at 33+ months. For details, see the article by Bhatia and colleagues on page 1185 of this issue.



Clinical Cancer Research

25 (4)

Clin Cancer Res 2019;25:1125-1437.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/25/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/25/4>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.